Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases
- 9 December 2014
- journal article
- review article
- Published by Wiley in Pediatric Pulmonology
- Vol. 50 (4), 410-419
- https://doi.org/10.1002/ppul.23133
Abstract
Summary Hydroxychloroquine (HCQ) is one of the drugs frequently used for the treatment of interstitial lung disease (ILD) in children (chILD). This use is off‐label and studies to analyze the effect and safety of HCQ in chILD are lacking. Therefore, a literature research on the usage of chloroquine (CQ) and HCQ in these conditions was done. Eighty‐five case reports and small series in the period from 1984 to 2013 were identified in which children with different diagnoses of ILD were treated with CQ or HCQ, sometimes in combination with other medication including steroids. A favorable response to HCQ or CQ was reported in 35 cases, whereas in the other cases the effect was negative or not clear. The dose of HCQ used was between 5 and 10 mg/kg body weight/day (bw/d). No pharmacokinetic studies have been done. The side effect profile in children seemed to be similar to that in adults. Most often gastrointestinal symptoms were reported. Three patients were found developing retinal changes during the treatment with CQ, whereas in none of the patients treated with HCQ retinal changes were reported. Based on retrospective case reports and small series likely to be reported with bias, the use of HCQ in chILD might be classified as safe. As no prospective data on efficacy and safety of HCQ in chILD are available, systematic collection is necessary. This may be achieved by web‐based registers like the European Management Platform for Childhood Interstitial Lung Diseases. Prospective and controlled investigations of HCQ in patients with chILD are mandatory. Pediatr Pulmonol.Keywords
Funding Information
- European Commission (FP7-305653-chILD-EU)
This publication has 82 references indexed in Scilit:
- Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patientsClinics, 2013
- Management of imported malaria in EuropeMalaria Journal, 2012
- Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritisAnnals Of The Rheumatic Diseases, 2012
- Interstitial lung diseases in childrenOrphanet Journal of Rare Diseases, 2010
- Incidence and classification of pediatric diffuse parenchymal lung diseases in GermanyOrphanet Journal of Rare Diseases, 2009
- Pharmacokinetics of Hydroxychloroquine and Its Clinical Implications in Chemoprophylaxis against Malaria Caused by Plasmodium vivaxAntimicrobial Agents and Chemotherapy, 2009
- Antimalarials for children: Indications, toxicities, and guidelinesJournal of the American Academy of Dermatology, 1993
- Treatment of lymphoid interstitial pneumonia with chloroquineThe Journal of Pediatrics, 1993
- Lupus profundus in children: Treatment with hydroxychloroquineJournal of the American Academy of Dermatology, 1987
- Fatal desquamative interstitial pneumonia in three infants siblingsThe Journal of Pediatrics, 1984